FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world

There is no prospective, randomised head‐to‐head trial comparing first‐line FOLFIRINOX and gemcitabine/nab‐paclitaxel in advanced pancreatic cancer. We assess real‐world effectiveness and quality of life (QoL) of both regimens using a new prognostic score. This analysis includes 1540 patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Marschner, Norbert, Hegewisch‐Becker, Susanna, Reiser, Marcel, von der Heyde, Eyck, Bertram, Mathias, Hollerbach, Stephan H., Kreher, Stephan, Wolf, Thomas, Binninger, Adrian, Chiabudini, Marco, Kaiser‐Osterhues, Anja, Jänicke, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087956/
https://www.ncbi.nlm.nih.gov/pubmed/36053905
http://dx.doi.org/10.1002/ijc.34271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087956/
https://www.ncbi.nlm.nih.gov/pubmed/36053905
http://dx.doi.org/10.1002/ijc.34271

Ejemplares similares